EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments
November 02, 2022 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
– Initiated Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD) and Phase 2 PAVIA clinical trial for non-proliferative diabetic retinopathy (NPDR) – – Presented positive...
EyePoint Pharmaceuticals Shareholder News: Johnson Fistel Encourages EYPT Shareholders with Losses to Contact the Firm Regarding Investigation
August 31, 2022 09:40 ET
|
Johnson Fistel, LLP
SAN DIEGO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether EyePoint Pharmaceuticals, Inc. (“EyePoint” or “the...
EyePoint Pharmaceuticals Appoints Jay S. Duker, M.D. as Chief Operating Officer
November 01, 2021 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...
EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU®
July 20, 2021 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve...